S.A.S.-500 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover S.a.s.-500, and what generic alternatives are available?
S.a.s.-500 is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in S.A.S.-500 is sulfasalazine. There are ten drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sulfasalazine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for S.a.s.-500
A generic version of S.A.S.-500 was approved as sulfasalazine by WATSON LABS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for S.A.S.-500?
- What are the global sales for S.A.S.-500?
- What is Average Wholesale Price for S.A.S.-500?
Summary for S.A.S.-500
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 141 |
| Patent Applications: | 199 |
| DailyMed Link: | S.A.S.-500 at DailyMed |
US Patents and Regulatory Information for S.A.S.-500
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvay | S.A.S.-500 | sulfasalazine | TABLET;ORAL | 083450-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
